Cancer and the Workplace

Total Page:16

File Type:pdf, Size:1020Kb

Cancer and the Workplace CA Cancer J Clin 1996;46:70-92 Cancer and the Workplace Jeanne Mager Stellman, PhD Steven D. Stellman, PhD, MPH Introduction makes to the total cancer burden, recog- Although occupationally related cancers nition and concern for cancers related to make up only a small fraction of all can- workplace exposures have been central cers, many environmental carcinogens themes in control of environmental car- have first been discovered in occupation- cinogens. There are several good reasons al settings. The estimate typically found for this. One is the unique nature of the in the scientific literature is that about workplace, which serves as a focal point two to eight percent of all human cancers in which large numbers of people may are of occupational origin.1 However, by be exposed to high concentrations of averaging the unexposed population in chemicals or other hazardous situations. with the exposed, such estimates tend to Another is that the very nature of work obscure the heavy toll that occupational creates a cohort for the kinds of epidemi- cancer can take on specific populations of ologic studies described below that can exposed workers. Among persons actual- help establish a cause-effect relationship ly exposed to carcinogens at work, risk es- between an environmental exposure and timates are much higher. For instance, cancer. It is because of the exposures to Morabia et al2 have put the attributable large doses and the opportunities to im- risk for lung cancer at 9.2 percent for men plement effective procedures for risk as- employed in occupations characterized sessment and control in the workplace by exposure to established carcinogens. that the study of occupational cancer For bladder cancer, the population attrib- plays so important a role in the control of utable risk from occupational exposures cancer in general. may exceed one case in five for men3 and Finally, perhaps the most important one in ten for women.4 reason to identify occupational carcino- Indeed, despite the relatively small gens and to elucidate their role in cancer “contribution” that occupational cancer causation is that occupational cancers are, for the most part, entirely pre- Dr. Jeanne Stellman is an Associate Professor of ventable through appropriate engineer- Clinical Public Health in the Division of Health ing, personnel practices, and strict gov- Policy and Management in the School of Public ernmental protective legislation. Health at Columbia University in New York, New The ultimate goal of collecting, eval- York. uating, and disseminating data on car- Dr. Steven Stellman is Chief of the Division of cinogenicity of occupational exposures is Epidemiology at the American Health Foundation in New York, New York. to develop strategies for prevention of disease. The most efficient strategy relies This work was supported in part by National Cancer Institute grants CA-17613, CA-63021, CA-68384, on primary prevention, that is, identifica- and CA-32617. tion and elimination of sources of expo- 70 Ca—A cancer Journal for Clinicians CA Cancer J Clin 1996;46:70-92 sure. Secondary prevention through timately presented as monographs, each screening of asymptomatic illness plays a of which contains a critical evaluation of lesser role, but may still be valuable in the carcinogenicity of one or more target specific workplaces. Recent advances in exposures. The evaluations take into ac- molecular biology have led to identifica- count many different types of informa- tion of tests that can identify workers ex- tion, including data from epidemiology, posed to various carcinogens. Such tests, experimental studies on rodents and oth- however, are at present extremely expen- er laboratory animals, in vitro studies sive, and their predictive value is no where appropriate, and other relevant greater than that of traditional industrial data including toxicity, metabolism, hygiene workplace evaluations. Occupa- genotoxicity, and metabolic studies. tional screening may have its greatest According to the IARC, “Each usefulness as a tool for educating workers monograph consists of a brief description to potential hazards in the workplace. of the chemical and physical properties of the agent; methods for its analysis; a description of the methods and volumes Identifying Human Carcinogens of production and use; data on occur- Despite the fact that more than six mil- rence and human exposure; summaries lion chemicals have already been identi- of case reports and epidemiologic studies fied and registered with the Chemical of cancer in humans; summaries of ex- Abstracts Service and more than 50,000 perimental carcinogenicity tests; a brief are estimated to be regularly used in com- description of other relevant biologic merce, probably fewer than 1,000 chemi- data, such as toxicity and genetic effects, cals or exposure situations have been that may indicate its possible mechanism scrutinized as to their potential for cancer of action; and an evaluation of its car- causation.5 Even so, the literature on cinogenicity.”6 Because the IARC peri- evaluation of cancer risks for even this odically revises its evaluations to reflect small fraction of known exposures is mas- accumulation of new data and evolution sive and not altogether consistent for of methods of assessment, the informa- many specific substances. Estimation of tion in these monographs is generally actual cancer risks to humans requires current and forms the basis of the sum- careful sifting and evaluation of large mary tables in this paper. quantities of data from many different studies. Since the early 1970s, an exten- Categories of Carcinogenicity to sive effort has been made to systematize the available data on cancer risks. A com- Humans prehensive methodology for assessment The IARC classifies the evidence for car- of human cancer risks has been devel- cinogenicity of specific exposures into oped by the International Agency for Re- four categories: sufficient, limited, or in- search on Cancer (IARC) that draws on adequate evidence of carcinogenicity or data from a variety of disciplines. evidence suggesting lack of carcinogenici- The IARC methods, which are ty. Sufficient evidence of carcinogenicity widely regarded as definitive, rely on the implies that a causal relationship has judgment of internationally recognized been established between exposure to the experts. Groups of scientists with exper- agent, mixture, or exposure circumstance tise in various disciplines are convened to and human cancer and that chance, bias, discuss and summarize the literature on and confounding have been ruled out individual carcinogens, groups of related with reasonable confidence. carcinogens, or in some cases entire in- Limited evidence of carcinogenicity dustries. These critical evaluations are ul- implies that a positive association has Vol. 46 No. 2 March/April 1996 71 Cancer and the workplace been observed between exposure to the vided into Group 2A, probably carcino- agent, mixture, or exposure circumstance genic to humans, and Group 2B, possibly and cancer for which a causal interpreta- carcinogenic to humans. These catego- tion is considered to be credible, but rizations take explicit note of the rele- chance, bias, or confounding cannot be vance of animal studies to human cancer ruled out with reasonable confidence. risk and are most often used to classify Inadequate evidence of carcino- substances for which human data may be genicity means that the available studies limited or inadequate but where animal are of insufficient quality, consistency, or data are deemed sufficient and mechanis- statistical power to permit a conclusion tically relevant to humans (Group 2A) or regarding the presence or absence of a less than sufficient but strongly support- causal association or that no data on can- ive of existing human data (Group 2B). cer in humans are available. The seemingly large number of Evidence suggesting lack of carcino- agents denoted as carcinogenic or proba- genicity means that there are several ade- bly carcinogenic (Groups 1 and 2A, quate studies covering the full range of N=117) is a reflection of the selection exposure levels that human beings are process for inclusion in the monographs. known to encounter that are mutually Agents are generally evaluated only when consistent in not showing a positive asso- substantial data bases already exist. These ciation between exposure to the agent data bases, in turn, have usually evolved and the studied cancer at any observed over a period of years in response to con- level of exposure. cerns of industry, workers, or the public. Tables 2 and 3 present the IARC Mono- Criteria for Evaluating graph groupings of known and probable Carcinogenicity Based on Total human carcinogens (Groups 1 and 2A) and typical uses or occurrences.7 Table 4 Evidence summarizes occupational exposure situa- A set of criteria analogous to those for as- tions that have been classified as falling sessing risk in human studies is used to into Groups 1, 2A, and 2B. classify cancer risk even when definitive human data are not available. This Some Examples of Exposures and process takes into account information from carcinogenesis bioassays and other Controls in Health Care experimental studies of animals along The history of occupational cancer identi- with toxicity and other biologic data. The fication and control has been recounted expert committee deliberations take into by many authors.8 The potential for account epidemiologic, animal, and other work-related cancers has been recog- types of data, including in vitro and meta- nized at least since the work of Ramazzini bolic studies where appropriate, from in the sixteenth century, and in fact our which an overall assessment of carcino- modern understanding of the influence of genicity to humans is synthesized within a environmental factors on human cancer scheme that consists of four broad is due in large measure to occupational groups. To date, 61 volumes of IARC studies, ironically many of them drawn Monographs have been published, and from the exposures of people in the 782 agents or exposure circumstances health care professions.
Recommended publications
  • PCHHAX Overview of Flaxseed Patent
    Available online a t www.derpharmachemica.com ISSN 0975-413X Der Pharma Chemica, 2016, 8(14):33-38 CODEN (USA): PCHHAX (http://derpharmachemica.com/archive.html) Overview of Flaxseed Patent Applications for the prevention and treatment of human cancer Sepideh Miraj Infertility Fellowship, Medicinal Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran _____________________________________________________________________________________________ ABSTRACT Flaxseed, Linum usitatissimum, is a member of the genus Linum in the family Linaceae. It is a food and fiber crop cultivated in cooler regions of the world. The aim of this study is to overview its anti-cancer and anti-tumor effects. This review article was carried out by searching studies in PubMed, Medline, Web of Science, and IranMedex databases up to 2016.totally, of 1 08 found articles, 41 articles were included. The search terms were “Flaxseed. ”, “therapeutic”, “pharmacological”, anticancer, anti-tumor. Various studies have shown that Flaxseed. Possess Anti-Breast Cancer properties, Anti-Breast tumors properties , Anti-Ovary cancer properties, Gut-associated diseases properties, Lung tumor properties, Inflammation properties, Anti-Skin Carcinogenesis properties, Pro- carcinogenic, Mastalgia properties, Aortic remodeling ,Anti-mammary Cancer effect ,Antioxidant and Antiproliferative ,Colon cancer properties, Esophagitis properties, Apoptosis properties. Flaxseed possess lots of therapeutic and pharmacological effects.in this study, its anticancer, anti-tumor effects was overviewed. Keywords : Flaxseed, therapeutic, pharmacological, anticancer, anti-tumor. _____________________________________________________________________________________________ INTRODUCTION It is proved that herbal medicine is effective in the treatment of many diseases [1-10].Flax, Linum usitatissimum , is a member of the genus Linum in the family Linaceae. It is a food and fiber crop cultivated in cooler regions of the world.
    [Show full text]
  • A Bibliometric Analysis
    787 Original Article Page 1 of 9 The 100 most cited articles on lung cancer screening: a bibliometric analysis Meng Li1,2, Qiang Cai2,3, Jing-Wen Ma1, Li Zhang1,2, Claudia I. Henschke2 1Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 2Department of Radiology, Mount Sinai Health System, New York, NY, USA; 3Department of Radiology, Shanxi Provincial People’s Hospital, Taiyuan, China Contributions: (I) Conception and design: M Li, CI Henschke; (II) Administrative support: CI Henschke; (III) Provision of study materials or patients: M Li, CI Henschke; (IV) Collection and assembly of data: M Li, L Zhang; (V) Data analysis and interpretation: M Li, Q Cai, JW Ma; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Claudia I. Henschke. Department of Radiology, Mount Sinai Health System, 1 Gustave Levy Place, New York, NY 10029, USA. Email: [email protected]. Background: The number of citations of an article reflects its impact on the scientific community. The aim of this study was to identify and characterize the 100 most cited articles on lung cancer screening. Methods: The 100 most cited articles on lung cancer screening published in all scientific journals were identified using the Web of Science database. Relevant data, including the number of citations, publication year, publishing journal and impact factor (IF), authorship and country of origin, article type and study design, screening modality, and main topic, were collected and analyzed. Results: The 100 most cited articles were all English and published between 1973 and 2017, with 81 published after 2000.
    [Show full text]
  • Cancer Treatment and Survivorship Facts & Figures 2019-2021
    Cancer Treatment & Survivorship Facts & Figures 2019-2021 Estimated Numbers of Cancer Survivors by State as of January 1, 2019 WA 386,540 NH MT VT 84,080 ME ND 95,540 59,970 38,430 34,360 OR MN 213,620 300,980 MA ID 434,230 77,860 SD WI NY 42,810 313,370 1,105,550 WY MI 33,310 RI 570,760 67,900 IA PA NE CT 243,410 NV 185,720 771,120 108,500 OH 132,950 NJ 543,190 UT IL IN 581,350 115,840 651,810 296,940 DE 55,460 CA CO WV 225,470 1,888,480 KS 117,070 VA MO MD 275,420 151,950 408,060 300,200 KY 254,780 DC 18,750 NC TN 470,120 AZ OK 326,530 NM 207,260 AR 392,530 111,620 SC 143,320 280,890 GA AL MS 446,900 135,260 244,320 TX 1,140,170 LA 232,100 AK 36,550 FL 1,482,090 US 16,920,370 HI 84,960 States estimates do not sum to US total due to rounding. Source: Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute. Contents Introduction 1 Long-term Survivorship 24 Who Are Cancer Survivors? 1 Quality of Life 24 How Many People Have a History of Cancer? 2 Financial Hardship among Cancer Survivors 26 Cancer Treatment and Common Side Effects 4 Regaining and Improving Health through Healthy Behaviors 26 Cancer Survival and Access to Care 5 Concerns of Caregivers and Families 28 Selected Cancers 6 The Future of Cancer Survivorship in Breast (Female) 6 the United States 28 Cancers in Children and Adolescents 9 The American Cancer Society 30 Colon and Rectum 10 How the American Cancer Society Saves Lives 30 Leukemia and Lymphoma 12 Research 34 Lung and Bronchus 15 Advocacy 34 Melanoma of the Skin 16 Prostate 16 Sources of Statistics 36 Testis 17 References 37 Thyroid 19 Acknowledgments 45 Urinary Bladder 19 Uterine Corpus 21 Navigating the Cancer Experience: Treatment and Supportive Care 22 Making Decisions about Cancer Care 22 Cancer Rehabilitation 22 Psychosocial Care 23 Palliative Care 23 Transitioning to Long-term Survivorship 23 This publication attempts to summarize current scientific information about Global Headquarters: American Cancer Society Inc.
    [Show full text]
  • Integrative Oncology from a Bibliometric Point of View T Jenny-Ann Brodin Danell
    Complementary Therapies in Medicine 52 (2020) 102477 Contents lists available at ScienceDirect Complementary Therapies in Medicine journal homepage: www.elsevier.com/locate/ctim Integrative oncology from a bibliometric point of view T Jenny-Ann Brodin Danell Department of Sociology, Umeå University, 901 87 Umeå, Sweden ARTICLE INFO ABSTRACT keywords: Objectives: The aim of this article is to analyze the development of integrative oncology from a bibliometric point Integrative oncology of view. The publication and citation patterns of publications are analyzed and their contents mapped. Complementary therapies Design: This study is based on bibliometric methods. The data sets consist of 7 025 respectively 4 990 pub- Research domain lications over the time period 1966-2016, shown in PubMed and Web of Science. Bibliometric methods Results: The expansion of the numbers of these publications took place in the late 1990s/early 2000s. Research is Citation analysis dominated by authors located in the USA, China and Germany who are working at well-established research Content analysis universities and university hospitals. The clinical share of publications is relatively small, and few studies are classified according to clinical phase. Content analysis revealed that much of the clinical research is based on surveys, and that content reflects the intersection of complementary therapies and cancer research. The latter aspect is less obvious in pre-clinical research. The most frequent journals in the material show a focus on complementary and alternative therapies or on integrative oncology, although journals focused on oncology or general/internal medicine were well-represented in the material as a whole. The most-cited publications were review articles and surveys.
    [Show full text]
  • An American Cancer Society Guide for Informed Choices Downloaded from Colleen Doyle, MS, RD; Lawrence H
    Downloaded from Nutrition and Physical Activity During and After Cancer Treatment: An American caonline.amcancersoc.org Cancer Society Guide for Informed Choices Colleen Doyle, Lawrence H. Kushi, Tim Byers, Kerry S. Courneya, Wendy Demark-Wahnefried, Barbara Grant, Anne McTiernan, Cheryl L. Rock, Cyndi Thompson, Ted Gansler, Kimberly S. Andrews and for the 2006 Nutrition, Physical Activity and Cancer Survivorship Advisory Committee CA Cancer J Clin 2006;56;323-353 DOI: 10.3322/canjclin.56.6.323 by on August 5, 2009 (©American Cancer Society, Inc.) This information is current as of August 5, 2009 The online version of this article, along with updated information and services, is located on the World Wide Web at: http://caonline.amcancersoc.org/cgi/content/full/56/6/323 To subscribe to the print issue of CA: A Cancer Journal for Clinicians, go to (US individuals only): http://caonline.amcancersoc.org/subscriptions/ CA: A Cancer Journal for Clinicians is published six times per year for the American Cancer Society by Wiley-Blackwell. A bimonthly publication, it has been published continuously since November 1950. CA is owned, published, and trademarked by the American Cancer Society, 250 Williams Street NW, Atlanta GA 30303. (©American Cancer Society, Inc.) All rights reserved. Print ISSN: 0007-9235. Online ISSN: 1542-4863. CA Cancer J Clin 2006;56:323–353 Nutrition and Physical Activity During and After Cancer Treatment: An American Cancer Society Guide for Informed Choices Downloaded from Colleen Doyle, MS, RD; Lawrence H. Kushi, ScD; Tim Byers, MD, MPH; Ms. Doyle is Director, Nutrition and Kerry S. Courneya, PhD; Wendy Demark-Wahnefried, PhD, RD, LDN; Barbara Grant, MS, Physical Activity, American Cancer Society, Atlanta, GA.
    [Show full text]
  • What Is the Relay for Life Movement? Join the W Orldwide
    What is the Relay For Life movement? Join the worldwide movement to end cancer. end to movement worldwide Join the Each American Cancer Society Relay For Life event gives everyone an opportunity to fight cancer and help save more lives. Teams made up of family members, friends, and/or coworkers camp out at a local school, park, or fairground and take turns walking American Cancer Society Relay For Life | RelayForLife.org 1.800.227.2345 around a track or path. Because cancer never sleeps, each team is asked to have a representative on the track at all times during the overnight event. Relay For Life is the signature fundraising event for the American Cancer Society. At the event, you will have the opportunity to celebrate cancer survivors, remember loved ones lost to the disease, and learn more about how to fight back against cancer. While you’re raising much-needed funds, you’ll also be raising awareness of the importance of cancer prevention, early detection, treatment, and patient support. Celebrate Survivors and Caregivers At Relay For Life events, cancer survivors and caregivers can come together and be recognized for their personal fight against a disease that has taken too much. In addition to a special ceremony, Survivors and Caregivers laps open the event and serve as a testament to the fight against cancer and the hope for a cure. All survivors and caregivers are invited to join their local Relay For Life event, no matter where their personal journey with cancer has taken them. Remember during the Luminaria Ceremony When the sun goes down, luminaria line the track, each one lit in honor or memory of those who have faced cancer – those who lost their battle, those who won, and those whose fight continues.
    [Show full text]
  • Download This PDF File
    Journal of Tumor Online Submissions: http: //www.ghrnet.org/index.php/jt Journal of Tumor 2021 May; 9(1): 579-586 DOI: 10.17554/j.issn.1819-6187.2021.09.130 ISSN 1819-6187 ORIGINAL ARTICLE Global Scientific Research Progress in Thyroid Cancer: A Bibliometric Analysis Hassan H. Musa1,2, Idriss H. Musa1,3, Mansour El-Sharief2, Taha H. Musa1,3,4* 1 Biomedical Research Institute, Darfur College, Nyala, Sudan; supported 25.68% of TC research. Journal of thyroid and journal 2 Faculty of Medical Laboratory Sciences, University of Khartoum, of clinical endocrinology and metabolism are the most productive Khartoum, Sudan; journals. Wang Y and Tuttle RM were the top productive, authors. 3 School of Medicine, Darfur College, Nyala, Sudan; Revised American thyroid association management guidelines for 4 Organization of African Academic Doctor (OAAD), Off Kamiti patients with thyroid nodules and differentiated thyroid cancer authored Road, P.O Box 25305000100, Nairobi, Kenya. by Cooper DS et al., published in 2009, was the most cited article. The most retrieved keywords were thyroid cancer, papillary thyroid cancer, Conflict-of-interest statement: The author(s) declare(s) that there and differentiated thyroid cancer. The study concludes that USA is no conflict of interest regarding the publication of this paper. institutes and funding agencies contribute to thyroid cancer research at a global level. Papillary thyroid cancer is a hot topic for research. Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external Key words: Thyroid cancer; Bibliometrics; Scopus; Web of Science reviewers.
    [Show full text]
  • (NCCN) Breast Cancer Clinical Practice Guidelines
    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer Version 5.2020 — July 15, 2020 NCCN.org NCCN Guidelines for Patients® available at www.nccn.org/patients Continue Version 5.2020, 07/15/20 © 2020 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. NCCN Guidelines Index NCCN Guidelines Version 5.2020 Table of Contents Breast Cancer Discussion *William J. Gradishar, MD/Chair ‡ † Sharon H. Giordano, MD, MPH † Sameer A. Patel, MD Ÿ Robert H. Lurie Comprehensive Cancer The University of Texas Fox Chase Cancer Center Center of Northwestern University MD Anderson Cancer Center Lori J. Pierce, MD § *Benjamin O. Anderson, MD/Vice-Chair ¶ Matthew P. Goetz, MD ‡ † University of Michigan Fred Hutchinson Cancer Research Mayo Clinic Cancer Center Rogel Cancer Center Center/Seattle Cancer Care Alliance Lori J. Goldstein, MD † Hope S. Rugo, MD † Jame Abraham, MD ‡ † Fox Chase Cancer Center UCSF Helen Diller Family Case Comprehensive Cancer Center/ Comprehensive Cancer Center Steven J. Isakoff, MD, PhD † University Hospitals Seidman Cancer Center Massachusetts General Hospital Amy Sitapati, MD Þ and Cleveland Clinic Taussig Cancer Institute Cancer Center UC San Diego Moores Cancer Center Rebecca Aft, MD, PhD ¶ Jairam Krishnamurthy, MD † Karen Lisa Smith, MD, MPH † Siteman Cancer Center at Barnes- Fred & Pamela Buffet Cancer Center The Sidney Kimmel Comprehensive Jewish Hospital and Washington Cancer Center at Johns Hopkins University School of Medicine Janice Lyons, MD § Case Comprehensive Cancer Center/ Mary Lou Smith, JD, MBA ¥ Doreen Agnese, MD ¶ University Hospitals Seidman Cancer Center Research Advocacy Network The Ohio State University Comprehensive and Cleveland Clinic Taussig Cancer Institute Cancer Center - James Cancer Hospital Hatem Soliman, MD † and Solove Research Institute P.
    [Show full text]
  • Get App Journal Flyer
    IMPACT FACTOR 6.639 an Open Access Journal by MDPI The Irish Association for Cancer Research (IACR), Signal Transduction Society (STS) and Spanish Association for Cancer Research (ASEICA) are affiliated with Cancers. IMPACT FACTOR 6.639 an Open Access Journal by MDPI Editor-in-Chief Message from the Editor-in-Chief Prof. Dr. Samuel C. Mok Cancers is an international, online journal addressing both clinical and basic science issues related to cancer Associate Editors Prof. Dr. David Wong research. The journal will continue its open access Dr. Deepak Nagrath format, which will certainly evolve to ensure that the Prof. Dr. Mary Frances McMullin journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment. Author Benefits Open Access Unlimited and free access for readers No Copyright Constraints Retain copyright of your work and free use of your article Thorough Peer-Review Rapid Processing and Immediate Publication upon Acceptance Coverage by Leading Indexing Services SCIE-Science Citation Index Expanded (Clarivate Analytics), PubMed (NLM), Scopus (Elsevier) No Space Constraints, No Extra Space or Color Charges No restriction on the length of the papers, number of figures or colors Discounts on Article Processing Charges (APC) If you belong to an institute that participates with the MDPI Institutional Open Access Program (IOAP) Aims and Scope Cancers features (1) Original Articles reporting on novel and original findings; (2) Clinical Observations accompanied by analysis and discussion; (3) Communications reporting small scale studies that include important new information; (4) timely Reviews and Topical Issues on cutting edge fields in oncology.
    [Show full text]
  • A SCIENTOMETRIC STUDY SHILPA B S Kuvempu University, [email protected]
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Library Philosophy and Practice (e-journal) Libraries at University of Nebraska-Lincoln Summer 4-1-2019 MAPPING OF SCIENTIFIC ARTICLES ON LEUKEMIA: A SCIENTOMETRIC STUDY SHILPA B S Kuvempu University, [email protected] Padmamma S Kuvempu University, [email protected] Arun Kumara T S Kuvempu University, [email protected] Walmiki Ramesh H Kuvempu University, [email protected] Follow this and additional works at: https://digitalcommons.unl.edu/libphilprac Part of the Library and Information Science Commons B S, SHILPA; S, Padmamma; T S, Arun Kumara; and H, Walmiki Ramesh, "MAPPING OF SCIENTIFIC ARTICLES ON LEUKEMIA: A SCIENTOMETRIC STUDY" (2019). Library Philosophy and Practice (e-journal). 2419. https://digitalcommons.unl.edu/libphilprac/2419 MAPPING OF SCIENTIFIC ARTICLES ON LEUKEMIA: A SCIENTOMETRIC STUDY Shilpa B. S1., Dr. Padmamma S2, Arun Kumara T. S3 and Dr. R.H. Walmiki4 1Research Scholar, Department of Library and Information Science, Kuvempu University, Shankaraghatta, Shimoga, Karnataka, India Email: [email protected] 2Professor, Department of Library and Information Science, Kuvempu University, Shankaraghatta, Shimoga, Karnataka, India Email: [email protected] 3Research Scholar, Department of Library and Information Science, Kuvempu University, Shankaraghatta, Shimoga, Karnataka, India Email: [email protected] 4Dr. R.H.Walmiki Librarian (I.C), University Library, Kuvempu University, Shimoga, Karnataka, India Email: [email protected] Abstract The study analyses the Leukemia research publications in India during 2009 to 2018based on the Web of Science database. The objectives of the study were to perform a scientometric analysis of all Leukemia research publications by Indian scientist. The parameters studies include growth of publications, document-wise distribution of records, country-wise distribution of publications, identification of most prolific authors, highly preferred journals and highly productive institutions.
    [Show full text]
  • Visualization and Bibliometric Analysis of Camp Signaling System Research
    Journal of Cancer 2021, Vol. 12 358 Ivyspring International Publisher Journal of Cancer 2021; 12(2): 358-370. doi: 10.7150/jca.47158 Research Paper Visualization and bibliometric analysis of cAMP signaling system research trends and hotspots in cancer Caoli Tang1, Duanya Liu1, Yongsheng Fan1, Jun Yu1, Cong Li1, Jianmei Su1,2 and Chunhong Wang1 1. Department of Preventive Medicine, School of Public Health, Wuhan University, Donghu Road 115, Wuhan 430071, Hubei, China. 2. Key Laboratory of Regional Development and Environmental Response, Faculty of Resources and Environmental Science, Hubei University, Friendship Avenue 368, Wuhan 430062, Hubei, China. Corresponding author: Department of Preventive Medicine, School of Public Health, Wuhan University, Donghu Road 115, Wuhan 430071, Hubei, China. E-mail address: [email protected] (J. Su); [email protected] (C. Wang). © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2020.04.18; Accepted: 2020.10.02; Published: 2021.01.01 Abstract Cyclic adenosine monophosphate (cAMP) is an essential second messenger that widely distributed among prokaryotic and eukaryotic organisms. cAMP can regulate various biological processes, including cell proliferation, differentiation, apoptosis and immune functions. Any dysregulation or alteration of cAMP signaling may cause cell metabolic disorder, immune dysfunction and lead to disease or cancer. This study aimed to conduct a scientometric analysis of cAMP signaling system in cancer field, and explored the research trend, hotspots and frontiers from the past decade. Relevant literatures published from 2009 to 2019 were collected in the Web of Science Core Collection database.
    [Show full text]
  • Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy
    molecules Review Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy Jiaqi Li 1, Jie Qing Eu 2, Li Ren Kong 2,3, Lingzhi Wang 2,4, Yaw Chyn Lim 2,5, Boon Cher Goh 2,4,6 and Andrea L. A. Wong 2,6,* 1 School of Clinical Medicine, University of Cambridge, Cambridge CB2 0SP, UK; [email protected] 2 Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore; [email protected] (J.Q.E.); [email protected] (L.R.K.); [email protected] (L.W.); [email protected] (Y.C.L.); [email protected] (B.C.G.) 3 Medical Research Council Cancer Unit, University of Cambridge, Cambridge CB2 0XZ, UK 4 Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore 5 Department of Pathology, National University Health System, Singapore 119074, Singapore 6 Department of Haematology-Oncology, National University Health System, Singapore 119228, Singapore * Correspondence: [email protected]; Tel.: +65-6779-5555 Academic Editors: Jacinta Serpa and Sofia C. Nunes Received: 29 September 2020; Accepted: 16 October 2020; Published: 20 October 2020 Abstract: Targeting altered tumour metabolism is an emerging therapeutic strategy for cancer treatment. The metabolic reprogramming that accompanies the development of malignancy creates targetable differences between cancer cells and normal cells, which may be exploited for therapy. There is also emerging evidence regarding the role of stromal components, creating an intricate metabolic network consisting of cancer cells, cancer-associated fibroblasts, endothelial cells, immune cells, and cancer stem cells.
    [Show full text]